NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
NEO Shareholders Click Here: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35898&wire=1
AVYA Shareholders Click Here: https://www.zlk.com/pslra-1/avaya-holdings-loss-submission-form?prid=35898&wire=1
YMAB Shareholders Click Here: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=35898&wire=1
* ADDITIONAL INFORMATION BELOW *
NeoGenomics, Inc. (NASDAQ:NEO)
NEO Lawsuit on behalf of: investors who purchased February 27, 2020 - April 26, 2022
Lead Plaintiff Deadline : February 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/neogenomics-lawsuit-submission-form?prid=35898&wire=1
According to the filed complaint, during the class period, NeoGenomics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."
Avaya Holdings Corp. (NYSE:AVYA)
AVYA Lawsuit on behalf of: investors who purchased November 22, 2021 - November 29, 2022
Lead Plaintiff Deadline : March 6, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/avaya-holdings-loss-submission-form?prid=35898&wire=1
According to the filed complaint, during the class period, Avaya Holdings Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's internal control over financial reporting was deficient in several areas; (ii) as a result of these deficiencies, the Company had failed to design and maintain effective controls over its whistleblower policies and its ethics and compliance program; (iii) the Company's deteriorating financial condition was likely to raise substantial doubt as to its ability to continue as a going concern; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
This lawsuit is on behalf of persons or entities who purchased shares of Y-mAbs Therapeutics, Inc. common stock on the open market or pursuant to registration statements filed with the U.S. Securities and Exchange Commission during the period October 6, 2020 through October 28, 2022, inclusive.
Lead Plaintiff Deadline : March 20, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/y-mabs-therapeutics-loss-submission-form?prid=35898&wire=1
According to the filed complaint, (i) Y-mAbs misrepresented the U.S. Food and Drug Administration's ("FDA") willingness to approve omburtamab, the Company's lead product candidate, for marketing based on the existing clinical trials; (ii) the Company misrepresented that progress was being made that would align with the FDA's requirements to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies; (iii) the FDA had repeatedly advised Y-mAbs that it was unlikely to grant approval for the marketing of omburtamab; and (iv) Y-mAbs had elected to submit the March 31, 2022 Biologics License Application prior to reaching agreement with the FDA on the content of the application.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP